✦ LIBER ✦

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

✍ Scribed by Edward J Gane; Stuart K Roberts; Catherine AM Stedman; Peter W Angus; Brett Ritchie; Rob Elston; David Ipe; Peter N Morcos; Linda Baher; Isabel Najera; Tom Chu; Uri Lopatin; M Michelle Berrey; William Bradford; Mark Laughlin; Nancy S Shulman; Patrick F Smith

Book ID: 117307284
Publisher: The Lancet
Year: 2010
Tongue: English
Weight: 316 KB
Volume: 376
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(10)61384-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Daclatasvir for previously untreated chr

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

✍ S. Pol; R. H. Ghalib; V. K. Rustgi; C. Martorell; G. T. Everson; H. A. Tatum; C. 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 205 KB

Combination therapy with thymosin α1 and

Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial

✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr